Related Experiment Videos

[Goals in risk factor reduction and therapeutic failures]

András Kali1, András Jánosi

  • 1Szent János Kórház, III, Belosztály Budapest.

Orvosi Hetilap
|March 3, 2006
PubMed

Insights

Vascular event risk factors like high cholesterol, blood sugar, and blood pressure are often not managed effectively in high-risk patients. Most patients fail to reach treatment goals, indicating a gap in current clinical practice.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Vascular Health

Context:

  • Cardiovascular disease remains a leading cause of mortality worldwide.
  • Effective management of modifiable risk factors is crucial for preventing vascular events.
  • High-risk patient populations often present complex challenges in achieving therapeutic targets.

Purpose:

  • To evaluate the achievement of therapeutic goals for three key modifiable risk factors: hyperlipidemia, hyperglycemia, and hypertension.
  • To compare target versus realized risk factor values in 350 high-risk patients.
  • To assess the effectiveness of current clinical practices in managing these risk factors.

Summary:

  • Analysis of 350 high-risk patients revealed suboptimal control of hyperlipidemia, hyperglycemia, and hypertension.
  • A significant number of patients remained untreated for hyperlipidemia (47.3%).
  • Despite treatment, many patients exceeded blood sugar and blood pressure goals, with only 5.2% achieving risk factor freedom.

Impact:

  • Current clinical practices are insufficient for achieving therapeutic goals in a majority of high-risk patients.
  • There is a critical need for improved strategies to manage hyperlipidemia, hyperglycemia, and hypertension.
  • The findings highlight a disconnect between treating conditions and achieving optimal patient outcomes, emphasizing the need for better risk factor control.
Abstract

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...